Arbor Biotechnologies
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) (NCT06839235) | Arbor Biotechnologies | 2025-06-16 |
Track Arbor Biotechnologies automatically
Every clearance here is in the API, with alerts when new ones post.